Welcome to the e-CCO Library!

P696: Ambient air quality as risk factor for microscopic colitis – a Geographic Information System study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Verhaegh B.P.M.*1,2, Beijnens E.M.3, van den Heuvel T.R.A.1, Goudkade D.4, Zeegers M.P.2,5, Nawrot T.S.3, Masclee A.A.M.1,2, Jonkers D.M.A.E.1,2, Pierik M.J.1

Created: Wednesday, 20 February 2019, 10:36 AM
P696: Design and rationale for the multicentre, randomised, controlled VERDICT trial to determine the optimal treatment target in patients with ulcerative colitis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Jairath, V.(1,2,3)*;Zou, G.(2,3,4);Radulescu, G.(3);Sigler, J.(3);Mcfarlane, S.C.(3);Adsul, S.(5);Freire, M.(5);Peyrin-Biroulet, L.(6);Colombel, J.F.(7);Moran, G.W.(8,9);Sebastian, S.(10,11);Travis, S.(12);Vermeire, S.(13);Sandborn, W.J.(14);D'Haens, G.R.(15); Feagan, B.G.(1,2,3);
Created: Friday, 14 July 2023, 11:12 AM
P696: Faecal microbiota transplantation in ultra-refractory ulcerative colitis: Retrospective analysis in a tertiary care centre
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Guerrero García1*, A. Flores de Miguel1, E. Sánchez Rodríguez1, R. Ríos León1, G. Roy Ariño2, R. Del Campo Moreno3, A. Albillos Martínez1, A. López-Sanromán1

Created: Thursday, 21 February 2019, 9:14 AM
P696: Genetic predisposition to infliximab immunogenicity in patients with immune-mediated inflammatory diseases – secondary analyses from a randomised clinical trial
Year: 2022
Source: ECCO'22
Authors: Bjørlykke, K.(1,2);Brun, M.K.(2,3);Viken, M.K.(4,5);Stenvik, G.E.(3);Klaasen, R.A.(6);Gehin, J.E.(2,6);Warren, D.J.(6);Sexton, J.(3);Haavardsholm, E.A.(2,3);Jahnsen, J.(1,2);Lie, B.A.(2,4,5);Goll, G.L.(3);Bolstad, N.(6);Syversen, S.W.(3);Jørgensen, K.K.(1);
Created: Friday, 11 February 2022, 3:56 PM
P696: Long-term prognosis and predictive factors for surgical treatment of intestinal lesions in patients with Behcet’s disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

T. Chohno*1, K. Watanabe1, T. Minagawa1, R. Kuwahara1, Y. Horio1, H. Sasaki1, T. Bando1, M. Uchino1, H. Ikeuchi1

Created: Friday, 22 February 2019, 9:41 AM
P697 Efficacy and safety of ustekinumab in Crohn’s disease: A real-world study from Australia
Year: 2020
Source:

ECCO'20 Vienna

Authors:

P. Kakkadasam Ramaswamy, H. Moattar, E. Sawyer, J. Edwards, D. Shukla

Created: Thursday, 30 January 2020, 10:12 AM
P697: Pneumocystis jirovecii pneumonia in IBD patients treated with immunomodulator(s)
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

S. Vieujean*1, A. Moens2, K. Rothfuss3, E. Savarino4, S. Vavricka5, C. Reenaers1, M. Ferrante2, J-F. Rahier6, ECCO CONFER Investigators1

Created: Friday, 22 February 2019, 9:41 AM
P697: Association of inflammatory bowel disease and celiac disease. Experience in a hospital of the autonomous community of Madrid (Spain)
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Manceñido Marcos N.*1, Pajares Villarroya R.1, Salinas Moreno S.2, Arribas Lόpez M.R.1, Comas Redondo C.1

Created: Wednesday, 20 February 2019, 10:36 AM
P697: De-escalating therapy in inflammatory bowel disease: Results from an observational study in clinical practice.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Arenas, A.(1,2,3)*;Moreta, M.J.(4);Ordás, I.(1,4);Fernández-Clotet, A.(1,4);Caballol, B.(1,4);Gallego, M.(1,4);Vara, A.(1,4);Barastegui, R.(1,4);Giner, A.(1,4);Prieto, C.(1,4);Masamunt, M.C.(1,4);Ricart, E.(1,4);
Created: Friday, 14 July 2023, 11:12 AM
P697: Examining the regulatory role of epigenetic and transcriptomic alterations in anti-TNF treatment response and disease progression in patients with Ulcerative Colitis
Year: 2022
Source: ECCO'22
Authors: Lawal, O.(1);Stack, R.(2);Ciara, E.(2);Tosetto, M.(2);McDonnell, C.(1);Rodriguez-Sosa, A.(1);Yochum, G.(3);Koltun, W.(3);Boland, K.(4);Sheahan, K.(5);Doherty, G.(2);Das, S.(1);
Created: Friday, 11 February 2022, 3:56 PM
P697: Thiopurines vs. anti-TNFa for the prevention of postoperative recurrence in Crohn’s disease—a meta-analysis
Year: 2018
Source: ECCO '18 Vienna
Authors:

E.M.J. Beelen1*, B. Oldenburg2, A.E. van der Meulen-de Jong3, C.I.J. Ponsioen4, G. Dijkstra5, M.J. Pierik6, F. Hoentjen7, N.K.H. de Boer8, N.S. Erler9, C.J. van der Woude1, A.C. de Vries1

Created: Thursday, 21 February 2019, 9:14 AM
P698 IBD patients equally tolerate bowel preparation but need higher doses of sedation during colonoscopy in comparison with a population screening programme: Results from a prospective, single-centre study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

C. Bezzio1, P. Andreozzi2, M. Schettino1, I. Arena1, C. Della Corte1, M. Devani1, G. Manes1, B. Omazzi1, S. Saibeni1

Created: Thursday, 30 January 2020, 10:12 AM
P698: Early dose optimisation in non-responders to golimumab induction treatment for ulcerative colitis is supported by pharmacokinetic data
Year: 2018
Source: ECCO '18 Vienna
Authors:

G. Philip1, C. Marano2, J. Adedokun2, R. Melsheimer3, F. Cornillie4*

Created: Thursday, 21 February 2019, 9:14 AM
P698: Mapping field cancerisation and clonal evolution in IBD colons with dysplasia and colorectal cancer
Year: 2022
Source: ECCO'22
Authors: Yalchin, M.(1);Curtius, K.(2);Nowinski, S.(3);Moorghen, M.(1);Kimberley, C.(3);Smith, K.(3);Baker, A.M.(3);Al-Bakir, I.(3);Mossner, M.(3);Nadhamuni, V.(3);Hart, A.(1);Graham, T.(3);
Created: Friday, 11 February 2022, 3:56 PM
P698: Persistence, clinical effectiveness and safety of vedolizumab in the post-marketing real clinical practice in Italy: a double-centre, 2-year experience in Crohn’s disease and ulcerative colitis patients
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Sartini*1, R. Solimando2, A. Curatolo1, M. C. Verga1, A. Bertani1, M. Di Girolamo3, A. Merighi2, E. Villa1

Created: Friday, 22 February 2019, 9:41 AM
P698: Role of an exclusion diet (reduced disaccharides, saturated fats, emulsifiers, red and ultraprocessed meats) in maintaining the remission of chronic inflammatory bowel diseases in adults
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Preda, C.M.(1)*;Istratescu, D.(2);Manuc, T.(2);Nitescu, M.(3);Louis, E.(4);Manuc, M.(2);Stroie, T.(2);Diculescu, M.(2);
Created: Friday, 14 July 2023, 11:12 AM
P698: The risk of developing subsequent immune mediated inflammatory diseases: a retrospective matched cohort study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Panaccione R.*1, Aletaha D.2, Davis M.3, Johnson S.3, Skup M.4, Garg V.4

Created: Wednesday, 20 February 2019, 10:36 AM
P699 The concordance of Short Form-36 Health Survey scores with Mayo scores in the tofacitinib ulcerative colitis clinical programme
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M.C. Dubinsky1, A.G. Bushmakin2, J.C. Cappelleri2, J. Woolcott3, P. Sharma4, E. Maller3, L. Salese3, A. Armuzzi5

Created: Thursday, 30 January 2020, 10:12 AM
P699: Faecal microbiota transplantation as treatment for recurrent clostridium difficile infections: a single-centre experience
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

C. Caenepeel*1, A. Schroë1, K. Van den Broeck2, M. Ferrante1,2, S. Vermeire1,2

Created: Friday, 22 February 2019, 9:41 AM
P699: Impact of adalimumab's patient support program on clinical outcomes in inflammatory bowel diseases: results from the COMPANION study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Marshall J.K.*1,2, Narula N.1, Lebovic G.3,4, Millson B.5, Charland K.5, Sung M.5, Gaetano T.6, McHugh K.6, Latour M.6, Laliberte M.-C.6

Created: Wednesday, 20 February 2019, 10:36 AM